Cinclus Pharma Cash Flow Conversion Efficiency

Latest as of June 2026: -0.425x

Cinclus Pharma cash flow conversion efficiency. Based on the latest financial reports, Cinclus Pharma (CINPHA) has a cash flow conversion efficiency ratio of -0.425x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-86.19 Million ≈ $-9.28 Million USD) by net assets (Skr202.70 Million ≈ $21.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cinclus Pharma (2022–2025)

Cash flow conversion efficiency of Cinclus Pharma from 2022 to 2025. This chart illustrates how Cinclus Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CINPHA stock price for real-time trading data and today's change.

Cinclus Pharma Cash Flow Conversion Ratio Explained

Cinclus Pharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cinclus Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cinclus Pharma ranked by their cash flow conversion efficiency. Also see Cinclus Pharma (CINPHA) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Bluecom Co. Ltd KQ:033560	0.002x
Xilio Development Inc NASDAQ:XLO	-0.260x
JKG Land Bhd KLSE:6769	0.154x
C3 Metals Inc V:CCCM	-0.010x
Permianville Royalty Trust NYSE:PVL	59.816x
Keum Kang Steel Co. Ltd KQ:053260	-0.014x
Kamux Suomi Oy HE:KAMUX	0.181x
N. B. I. Industrial Finance Company Limited NSE:NBIFIN	0.002x

Annual Cash Flow Conversion Efficiency for Cinclus Pharma (2022–2025)

The table below shows the annual cash flow conversion efficiency of Cinclus Pharma from 2022 to 2025. Review Cinclus Pharma free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr369.39 Million ≈ $39.75 Million	Skr-74.65 Million ≈ $-8.03 Million	-0.202x	+37.08%
2024-12-31	Skr555.33 Million ≈ $59.76 Million	Skr-178.37 Million ≈ $-19.20 Million	-0.321x	-111.79%
2023-12-31	Skr-76.80 Million ≈ $-8.26 Million	Skr-209.19 Million ≈ $-22.51 Million	2.724x	+279.92%
2022-12-31	Skr126.87 Million ≈ $13.65 Million	Skr-192.08 Million ≈ $-20.67 Million	-1.514x	--

About Cinclus Pharma

ST:CINPHA Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$57.09 Million

Skr530.53 Million SEK

Market Cap Rank

#21175 Global

#385 in Sweden

Share Price

Skr11.40

Change (1 day)

-2.06%

52-Week Range

Skr10.82 - Skr19.46

All Time High

Skr42.00